[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"leukemia-acute-myeloid-aml\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:leukemia-acute-myeloid-aml":38},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":5},"100484287",false,"NCT05586074","HEC73543 Versus Salvage Chemotherapy in R\u002FR FLT3-ITD AML","HEC73543 Versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukemia: a Multicenter, Open-label, Randomized Phase 3 Trial","Inclusion Criteria:\n\n* Subject is ≥ 18 years of age at the time of obtaining informed consent.\n* Subject has a diagnosis of primary acute myeloid leukemia (AML) or AML secondary to myelodysplastic syndrome (MDS) according to WHO classification;\n* Subject is refractory to or relapsed after first-line AML therapy (with or without hematopoietic stem cell transplant )\n* Subject is positive for FLT3 mutation in bone marrow or whole blood as determined by the central lab\n* Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Subject is eligible for pre-selected salvage chemotherapy at the investigator's discretion\n\nExclusion Criteria:\n\n* Subject has received prior treatment with other FLT3 inhibitors\n* Subject has AML that has relapsed after or is refractory to more than 1 line of therapy\n* Subject has an active uncontrolled infection\n* Subject is known to have human immunodeficiency virus infection\n* Subject has any condition which, in the investigator's opinion, makes the subject unsuitable for study participation","ALL","18 Years",{"count":18,"type":19},324,"ESTIMATED","INTERVENTIONAL",[22],"PHASE3","A randomized，multicenter, open-label Phase III, clinical study is conducted to evaluate the clinical benefit Clifutinib in Chinese patients with relapsed\u002F refractory (R\u002FR) FLT3-mutated AML as shown with overall survival compared to salvage chemotherapy, and also to investigate the efficacy of Clifutinib as assessed by CR\u002FCRh rate in these subjects.",[25],"Leukemia, Acute Myeloid (AML)","RECRUITING","2026-04-27",{"date":29,"type":30},"2026-04-28","ACTUAL",{"date":32,"type":30},"2023-03-03",{"date":34,"type":19},"2028-05-30",{"name":36,"class":37},"Sunshine Lake Pharma Co., Ltd.","INDUSTRY",""]